<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lenvatinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lenvatinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lenvatinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="100044" href="/d/html/100044.html" rel="external">see "Lenvatinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F27277214"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lenvima (10 MG Daily Dose);</li>
<li>Lenvima (12 MG Daily Dose);</li>
<li>Lenvima (14 MG Daily Dose);</li>
<li>Lenvima (18 MG Daily Dose);</li>
<li>Lenvima (20 MG Daily Dose);</li>
<li>Lenvima (24 MG Daily Dose);</li>
<li>Lenvima (4 MG Daily Dose);</li>
<li>Lenvima (8 MG Daily Dose)</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871900"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lenvima (10 MG Daily Dose);</li>
<li>Lenvima (12 MG Daily Dose);</li>
<li>Lenvima (14 MG Daily Dose);</li>
<li>Lenvima (18 MG Daily Dose);</li>
<li>Lenvima (20 MG Daily Dose);</li>
<li>Lenvima (24 MG Daily Dose);</li>
<li>Lenvima (4 MG Daily Dose);</li>
<li>Lenvima (8 MG Daily Dose)</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F27157980"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F27378082"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Lenvatinib is associated with a moderate or high emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>). Prior to treatment initiation, correct electrolyte abnormalities and control BP. Withhold lenvatinib for at least 1 week prior to elective surgery; do not administer lenvatinib for at least 2 weeks following major surgery and until adequate wound healing. Prior to initiation, perform appropriate preventive dentistry and encourage good oral hygiene. Avoid invasive dental procedures in patients receiving lenvatinib, especially if at increased risk; withhold lenvatinib therapy for ≥1 week prior to scheduled dental surgery or invasive dental procedures.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6d001b2-4849-4994-a91e-d5920f3dc04e">Endometrial carcinoma, advanced, mismatch repair proficient or not microsatellite instability-high</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial carcinoma, advanced, mismatch repair proficient or not microsatellite instability-high:</b>
<b>Oral:</b> 20 mg once daily (in combination with pembrolizumab), continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35045221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35045221'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bea91e4d-a7de-4963-92b0-ea5efc19008f">Hepatocellular carcinoma, unresectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma, unresectable:</b>
<b>Oral:</b> 12 mg once daily (patients ≥60 kg [actual body weight]) or 8 mg once daily (patients &lt;60 kg [actual body weight]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29433850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29433850'])">Ref</a></span>); continue until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01ba1574-d28e-491e-b878-10259e42f21d">Renal cell carcinoma, advanced, first-line combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced, first-line combination therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with pembrolizumab: </i>
<b>Note: </b>May be used in combination with pembrolizumab regardless of risk stratification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33616314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33616314'])">Ref</a></span>); some experts may prefer this combination in patients with intermediate- or poor-risk disease who have symptomatic or life-threatening disease burden (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-George.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-George.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 20 mg once daily (in combination with pembrolizumab); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33616314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33616314'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with everolimus (off-label combination): </i>
<b>Note: </b>May be used in combination with everolimus regardless of risk stratification in patients who are ineligible for (or who decline) initial treatment with immunotherapy-based combinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-George.1','lexi-content-ref-33616314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-George.1','lexi-content-ref-33616314'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 18 mg once daily (in combination with everolimus); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33616314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33616314'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ca73afa7-b15b-4cf7-8ab6-07cb69e59723">Renal cell carcinoma, advanced, previously treated, combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced, previously treated, combination therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with everolimus: </i>
<b>Note: </b>May be used in combination with everolimus following prior antiangiogenic therapy, or in patients with progression after initial immunotherapy and who have not previously received antiangiogenic therapy, or after initial combination therapy (immunotherapy plus an antiangiogenic agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-George.1','lexi-content-ref-26482279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-George.1','lexi-content-ref-26482279'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 18 mg once daily (in combination with everolimus); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26482279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26482279'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="850bfdd3-abb4-44e1-aa1b-19ed5e9e4324">Thyroid cancer, differentiated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, differentiated:</b>
<b>Oral:</b> 24 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25671254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25671254'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> Do not take a missed dose within 12 hours of the next dose (if within 12 hours, skip the missed dose and return to regular administration time).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991385"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> CrCl calculated by Cockcroft-Gault equation (using actual body weight).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting renal impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Endometrial carcinoma, advanced:</i> 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hepatocellular carcinoma, unresectable: </i>There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Renal cell cancer, advanced:</i> 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Thyroid cancer, differentiated:</i> 14 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Lenvatinib is not expected to be dialyzable (due to high protein binding).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal toxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Nephrotic syndrome: Permanently discontinue lenvatinib.</p>
<p style="text-indent:-2em;margin-left:4em;">Proteinuria ≥2 g proteinuria/24 hours: Withhold lenvatinib; resume lenvatinib at a reduced dose when improved to &lt;2 g proteinuria/24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Renal failure or impairment (grade 3 or 4): Withhold lenvatinib; if improves to ≤ grade 1 or baseline, depending on the severity and persistence, resume lenvatinib at a reduced dose or permanently discontinue therapy.</p></div>
<div class="block doha drugH1Div" id="F50988590"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting hepatic impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Endometrial carcinoma, advanced:</i> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hepatocellular carcinoma, unresectable: </i>There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Renal cell cancer, advanced:</i> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Thyroid cancer, differentiated:</i> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Endometrial carcinoma, advanced:</i> 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hepatocellular carcinoma, unresectable: </i>There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Renal cell cancer, advanced:</i> 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Thyroid cancer, differentiated:</i> 14 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment (grade 3 or 4):</b> Withhold lenvatinib; if improves to ≤ grade 1 or baseline, depending on the severity and persistence, resume lenvatinib at a reduced dose or permanently discontinue therapy. Permanently discontinue lenvatinib for hepatic failure.</p></div>
<div class="block dot drugH1Div" id="F27378086"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption>
<b>Recommended Lenvatinib Dose Reductions for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Indication</p></th>
<th align="center">
<p style="text-indent:0em;">Usual lenvatinib dosage</p></th>
<th align="center">
<p style="text-indent:0em;">First dose reduction to:</p></th>
<th align="center">
<p style="text-indent:0em;">Second dose reduction to:</p></th>
<th align="center">
<p style="text-indent:0em;">Third dose reduction to:</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>When used in combination with pembrolizumab, modify the dose of one or both drugs as appropriate; withhold, reduce dose, or discontinue lenvatinib as appropriate. Refer to pembrolizumab monograph for dosage modification information.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>When used in combination with everolimus, for adverse reactions of both lenvatinib and everolimus, withhold or reduce the lenvatinib dose first and then the everolimus dose (refer to Everolimus monograph for dosage modification information).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Endometrial carcinoma (advanced)<sup class="footnote-number">a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">20 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">14 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hepatocellular carcinoma (unresectable); ≥60 kg</p></td>
<td align="center">
<p style="text-indent:0em;">12 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg once every other day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hepatocellular carcinoma (unresectable); &lt;60 kg</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg once every other day</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal cell carcinoma (advanced), first-line therapy<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">20 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">14 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal cell carcinoma (advanced), previously treated<sup class="footnote-number">b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">18 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">14 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Thyroid cancer (differentiated)</p></td>
<td align="center">
<p style="text-indent:0em;">24 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">14 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg once daily</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption>
<b>Adverse Reactions Requiring Dose Modification of Lenvatinib</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Lenvatinib dosage modification</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>If lenvatinib is discontinued, a drop in BP is expected and antihypertensive therapy should be reduced and/or interrupted as clinically appropriate (ESC [Lyon 2022]).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Hypertension</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">If indicated, initiate appropriate antihypertensive therapy<sup>a</sup> to reduce the risk for cardiovascular complications (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold lenvatinib for grade 3 hypertension that persists despite optimal antihypertensive therapy. When hypertension is controlled at ≤ grade 2, resume lenvatinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue lenvatinib.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Cardiac dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold lenvatinib until improves to ≤ grade 1 or baseline. Depending on the severity and persistence of the cardiac dysfunction, resume lenvatinib at a reduced dose or discontinue.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue lenvatinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">QTc prolongation</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">&gt;500 msec or &gt;60 msec increase from baseline</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold lenvatinib until improves to ≤480 msec or baseline, then resume lenvatinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Arterial thrombotic event</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue lenvatinib. The safety of resuming therapy after an arterial thrombotic event has not been established.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">GI perforation</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue lenvatinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Fistula formation</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue lenvatinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Reversible posterior leukoencephalopathy syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold lenvatinib until fully resolved; depending on severity and persistence of neurologic symptoms, resume lenvatinib at a reduced dose or discontinue.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:center;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Persistent or intolerable grade 2 or 3 adverse reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold lenvatinib until improves to ≤ grade 1 or baseline and then resume lenvatinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4 laboratory abnormality</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold lenvatinib until improves to ≤ grade 1 or baseline and then resume lenvatinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4 adverse reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue lenvatinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Diarrhea</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">Initiate prompt management of diarrhea or dehydration/hypovolemia. Based on the severity, withhold lenvatinib and upon recovery, resume lenvatinib at a reduced dose or permanently discontinue.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hemorrhage</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">Withhold lenvatinib; upon recovery (depending on severity), resume lenvatinib at a reduced dose or permanently discontinue treatment.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hypocalcemia</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">Administer calcium replacement therapy as necessary; withhold lenvatinib and resume at a reduced dose or permanently discontinue lenvatinib depending on the severity.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hypothyroidism</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">Manage hypothyroidism according to standard medical practice.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Osteonecrosis of the jaw</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">Withhold lenvatinib; restart after adequate resolution based on clinical judgement.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Wound healing complications</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Permanently discontinue lenvatinib. The safety of resuming lenvatinib after resolution of wound healing complications has not been established.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F27378083"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F27386862"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (45% to 73%; severe hypertension: 3%), peripheral edema (14% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (12%), palmar-plantar erythrodysesthesia (27% to 32%), skin rash (14% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (grades 3/4: 15%), hypothyroidism (21%), increased gamma-glutamyl transferase (grades 3/4: 17%), increased thyroid stimulating hormone level (57% to 70%), weight loss (31% to 51%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (30% to 31%), constipation (16% to 29%), decreased appetite (34% to 54%), diarrhea (39% to 67%), dysgeusia (18%), dyspepsia (13%), nausea (20% to 47%), stomatitis (11% to 41%; grades 3/4: ≤5%), vomiting (16% to 36%), xerostomia (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (26% to 34%), urinary tract infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (23%, including carotid artery hemorrhage; grades 3/4: 4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (15%; severe: 3%), increased serum aspartate aminotransferase (grades 3/4: 5% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (15%), fatigue (44% to 67%), headache (10% to 38%), insomnia (12%), mouth pain (25%), voice disorder (24% to 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤62%), myalgia (≤62%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (7% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (24%), epistaxis (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thromboembolism (2% to 5%), cardiac failure (grades ≥3: ≤3%), cardiomyopathy (grades ≥3: ≤3%), hypotension (9%), prolonged QT interval on ECG (8% to 9%; &gt;500 msec: 2%), pulmonary embolism (3%), reduced ejection fraction (ejection fraction reduced by &gt;20%: grades ≥3: ≤3%), ventricular dysfunction (grade ≥3: ≤3%; ventricular hypokinesia: grades ≥3: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperkeratosis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (9%; severe dehydration: 3%), hypercalcemia (&gt;5%), hypercholesterolemia (&gt;5%), hyperkalemia (&gt;5%), hypoalbuminemia (&gt;5%), hypocalcemia (grades 3/4: 9%), hypoglycemia (&gt;5%), hypokalemia (grades 3/4: 3% to 6%), hypomagnesemia (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal fistula (≤2%), gastrointestinal perforation (≤2%), increased serum amylase (&gt;5%), increased serum lipase (grades 3/4: 4% to 6%), infection of mouth (≤10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (grades 3/4: 4%), lymphocytopenia (grades 3/4: 8%), neutropenia (grades 3/4: 7%), thrombocytopenia (grades 3/4: 2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic encephalopathy (≤8%; severe: 5%), hepatic coma (≤8%), hepatic failure (3%), hyperbilirubinemia (&gt;5%), increased serum alanine aminotransferase (grades 3/4: 4% to 8%), increased serum alkaline phosphatase (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy (≤8%, including metabolic encephalopathy)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (grades 3/4: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (acute), hepatorenal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Reversible posterior leukoencephalopathy syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteonecrosis of the jaw</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Aneurysm (arterial), aortic aneurysm, aortic dissection, coronary artery dissection, myocardial rupture (arterial rupture and aortic rupture)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment</p></div>
<div class="block coi drugH1Div" id="F27157983"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Canadian labeling: Hypersensitivity to lenvatinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F27377922"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac effects: Hypertension commonly occurred in patients treated with lenvatinib in clinical trials (including grade 3 and 4 events); the median time to onset of new or worsening hypertension was 16 to 35 days. Serious complications have been reported secondary to poorly controlled hypertension. Serious (≥ grade 3) and fatal cardiac dysfunction has been reported with lenvatinib, including cardiomyopathy, left or right ventricular dysfunction, decreased left or right ejection fraction (&gt;20% from baseline), heart failure, cardiac failure, or ventricular hypokinesia. QT/QTc prolongation was also observed in lenvatinib-treated patients, including prolongation &gt;500 msec and increases &gt;60 msec from baseline.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fistula formulation/GI perforation: Fistulas and GI perforations have been reported with lenvatinib.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Diarrhea has commonly occurred in patients receiving lenvatinib; grade 3 events have been reported. When used in combination with everolimus, diarrhea was the most frequent cause of dose interruption and/or reduction, and diarrhea recurred despite dose reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Serious and fatal hemorrhagic events may occur with lenvatinib. Hemorrhagic events (any grade) occurred in over 25% of patients treated with lenvatinib (either as a single agent or in combination with everolimus); epistaxis and hematuria were the most frequently reported hemorrhagic events. Fatal intracranial hemorrhage was observed in a patient who had CNS metastases at baseline and received lenvatinib; cerebral hemorrhage has been reported in patients who received lenvatinib in combination with everolimus (including rare fatal cases). Serious tumor-related bleeding events (including cases of fatal hemorrhage) have been observed. Serious and fatal carotid artery hemorrhages were reported more frequently in patients with anaplastic thyroid carcinoma (ATC) than with other tumor types. Safety and efficacy of lenvatinib have not been established in the treatment of ATC. Consider the risk of severe or fatal hemorrhage associated with tumor infiltration/invasion of major blood vessels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious hepatic adverse reactions were observed in patients with malignancies other than hepatocellular cancer (HCC) who received lenvatinib; fatal events, including hepatic failure, acute hepatitis, and hepatorenal syndrome, have occurred. Hepatic encephalopathy (including hepatic encephalopathy, encephalopathy, metabolic encephalopathy, and hepatic coma) have been reported in lenvatinib-treated patients with HCC, including ≥ grade 3 events and hepatic failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Grade 3 to 4 hypocalcemia has occurred in patients receiving lenvatinib; in most cases, hypocalcemia improved or resolved following calcium supplementation, with or without treatment interruption or dosage reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: Lenvatinib impairs exogenous thyroid suppression. Most patients with differentiated thyroid cancer (DTC) had a baseline thyroid stimulating hormone (TSH) level ≤0.5 milliunits/L, however, in patients with DTC with a normal baseline TSH, elevation of TSH level &gt;0.5 milliunits/L was commonly observed. Grade 1 or 2 hypothyroidism also occurred in patients receiving lenvatinib for other indications; an elevation of TSH was commonly observed in patients with a normal or low TSH at baseline.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported with lenvatinib. Risk factors for ONJ include bisphosphonate or denosumab therapy, dental disease, and/or invasive dental procedures. Discontinuing bisphosphonate therapy in patients requiring invasive dental procedures may reduce the risk of ONJ. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with other antiangiogenic agents used as anticancer therapy. Angiogenic agents, when given concomitantly with antiresorptive agents, are associated with an increased risk of ONJ. The AAOMS suggests that if medically permissible, delay the initiation of antiangiogenic agents for cancer therapy until optimal dental health is attained (if extractions are required, antiangiogenesis therapy should be delayed until the extraction site has mucosalized or until after adequate osseous healing). Once antiangiogenic therapy for oncologic disease is initiated, procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Proteinuria (including grade 3 toxicity) was commonly observed in clinical studies. Serious renal impairment or failure may also occur (including ≥ grade 3 events and fatal renal failure); a primary risk factor for renal impairment is dehydration or hypovolemia due to diarrhea and vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">• Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome has occurred (rarely).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Arterial thromboembolic events, including ≥ grade 3 events, have been reported. Myocardial infarction and cerebrovascular events have occurred. Lenvatinib has not been studied in patients who have had an arterial thromboembolic event within the preceding 6 months.</p>
<p style="text-indent:-2em;margin-left:4em;">• Wound healing impairment: Vascular endothelial growth factor receptor inhibitors, including lenvatinib, are associated with impaired wound healing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥75 years of age appeared to have reduced tolerability for lenvatinib in some studies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) advanced endometrial carcinoma, select patients for treatment based on tumor specimen pMMR or MSI-H status. Information on approved tests may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=99962" target="_blank">http://www.fda.gov/companiondiagnostics</a>.</p></div>
<div class="block dosfc drugH1Div" id="F27339507"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Each Lenvima Therapy Pack contains a 30 day supply of dosage units</p></div>
<div class="block foc drugH1Div" id="F27277215"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (10 MG Daily Dose): 10 mg (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (12 MG Daily Dose): 3x4 mg (15 ea, 90 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (14 MG Daily Dose): 10 mg &amp; 4 mg (60 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (18 MG Daily Dose): 10 mg &amp; 2x4 mg (15 ea, 90 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (20 MG Daily Dose): 2x10 mg (60 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (24 MG Daily Dose): 2x10 mg &amp; 4 mg (90 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (4 MG Daily Dose): 4 mg (5 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (8 MG Daily Dose): 2x4 mg (10 ea, 60 ea)</p></div>
<div class="block geq drugH1Div" id="F27277213"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F27658121"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Lenvima (10 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $970.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Lenvima (12 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 x 4 mg (per each): $323.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Lenvima (14 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 &amp; 4 mg (per each): $485.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Lenvima (18 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 MG &amp;2 x 4 MG (per each): $323.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Lenvima (20 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 x 10 mg (per each): $485.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Lenvima (24 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 x 10 MG &amp;4 MG (per each): $323.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Lenvima (4 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $970.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Therapy Pack</b> (Lenvima (8 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 x 4 mg (per each): $485.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871901"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (10 MG Daily Dose): 10 mg (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (12 MG Daily Dose): 3 x 4 MG (6 ea, 90 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (14 MG Daily Dose): 10 &amp; 4 MG (60 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (18 MG Daily Dose): 10 MG &amp; 2 x 4 MG (90 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (20 MG Daily Dose): 2 x 10 MG (60 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (24 MG Daily Dose): 2 x 10 MG &amp; 4 MG (90 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (4 MG Daily Dose): 4 mg (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lenvima (8 MG Daily Dose): 2 x 4 MG (60 ea)</p></div>
<div class="block accres drugH1Div" id="F27377699"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Lenvatinib is available only through specialty pharmacies. For further information on patient assistance, product availability, and prescribing instructions, please refer to the following website: http://www.eisaireimbursement.com/patient/lenvima
                  </p></div>
<div class="block adm drugH1Div" id="F27378092"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Lenvatinib is associated with a moderate or high emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer at the same time each day. May be administered with or without food. Swallow capsules whole.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>For patients unable to swallow whole capsules, a suspension may be prepared for oral administration or for feeding tube administration:</i> Place dose (up to a maximum of 5 capsules) in a small container (~20 mL capacity) or a 20 mL syringe; do not break or crush capsules. Add 3 mL of liquid (use water or apple juice for oral administration; use water <b>only</b> for feeding tube administration) to the container or syringe and wait 10 minutes for the capsule shell (outer surface) to disintegrate, then stir or shake mixture for 3 minutes until capsules are fully disintegrated. Administer contents. Using a second syringe or dropper, add an additional 2 mL liquid to the container or syringe and swirl or shake and then administer; repeat this step at least once and until there is no more visible residue to ensure the full dose is administered. If 6 capsules are required for the dose, follow the above instructions using 3 capsules at a time. Suspension may be stored refrigerated in a covered container for up to 24 hours (discard if not administered within 24 hours). Compatibility has been confirmed for polypropylene syringes and for feeding tubes of at least 5 French diameter (PVC or polyurethane tube) or 6 French diameter (silicone tube).</p></div>
<div class="block hazard drugH1Div" id="F49132642"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Lenvatinib may be teratogenic, cause reproductive toxicity, and has a structural/toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F27157982"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial carcinoma, advanced: </b>Treatment of advanced endometrial carcinoma (in combination with pembrolizumab) that is mismatch repair proficient (as determined by an approved test), or not microsatellite instability-high, in patients who have disease progression following prior systemic therapy (in any setting) and are not candidates for curative surgery or radiation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma, unresectable:</b> First-line treatment of unresectable hepatocellular carcinoma (HCC).</p>
<p style="text-indent:-2em;margin-left:4em;">According to guidelines from the American Society of Clinical Oncology for systemic therapy for advanced HCC, lenvatinib is a first-line option for select patients with advanced HCC with Child-Pugh class A hepatic impairment, performance status of 0 or 1, and with contraindications to atezolizumab and/or bevacizumab therapy. Lenvatinib is a second-line therapy option in patients who received first-line therapy with atezolizumab and bevacizumab (ASCO [Gordan 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced:</b></p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment of advanced renal cell carcinoma (RCC) (in combination with pembrolizumab) in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of advanced RCC (in combination with everolimus) in adults following 1 prior anti-angiogenic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, differentiated:</b> Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.</p></div>
<div class="block mst drugH1Div" id="F27377697"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lenvatinib may be confused with cabozantinib, enasidenib, lapatinib, larotrectinib, lonafarnib, lorlatinib, neratinib, sorafenib, tivozanib, vandetanib</p>
<p style="text-indent:-2em;margin-left:4em;">Lenvima may be confused with Lynparza</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F27164162"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F27164159"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Citalopram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin-Containing Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Dronedarone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of DroPERidol.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Gemifloxacin.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May enhance the QTc-prolonging effect of Lenvatinib. Ketoconazole (Systemic) may increase the serum concentration of Lenvatinib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levofloxacin-Containing Products (Systemic): QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Levofloxacin-Containing Products (Systemic).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of Methadone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Osimertinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pacritinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of other QT-prolonging Kinase Inhibitors (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Kinase Inhibitors (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparfloxacin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Lenvatinib may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F51822193"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration with a high fat meal (~900 calories; ~55% from fat, ~15% from protein, and ~30% from carbohydrates) decreased the rate of absorption and delayed the median T<sub>max</sub> from 2 hours to 4 hours, but did not affect the extent of absorption. May be administered with or without food.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307979"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to lenvatinib initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during lenvatinib treatment and for 30 days after the last lenvatinib dose.</p></div>
<div class="block pri drugH1Div" id="F27377702"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and findings from animal reproduction studies, lenvatinib may cause fetal harm if administered in pregnancy.</p></div>
<div class="block brc drugH1Div" id="F27377704"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;margin-left:0em;display:inline">It is not known if lenvatinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during lenvatinib treatment and for 1 week after the last lenvatinib dose.</p></div>
<div class="block mop drugH1Div" id="F27378102"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Mismatch repair proficient status or not microsatellite instability-high status (in advanced endometrial carcinoma). LFTs (at baseline, every 2 weeks for 2 months, and at least monthly thereafter); renal function; electrolytes (baseline and periodically); serum calcium at least monthly; thyroid function (TSH levels) at baseline and monthly or as clinically indicated; monitor for proteinuria at baseline and periodically during treatment (urine dipstick; if 2+ then obtain a 24-hour urine protein). Verify pregnancy status prior to treatment initiation (in patients who could become pregnant). Monitor BP after 1 week, then every 2 weeks for 2 months, and at least monthly thereafter. Dental exam prior to and periodically during treatment. ECG in select patients (congenital long QT syndrome, heart failure, bradyarrhythmias, or in those on concomitant medications known to prolong the QT interval). Monitor for clinical signs/symptoms of cardiac dysfunction, arterial thrombosis, reversible posterior leukoencephalopathy syndrome (confirm with MRI), fistula formation, GI perforation, bleeding/hemorrhagic events, diarrhea, dehydration, and wound healing complications; monitor patients with hepatocellular carcinoma closely for signs of hepatic failure, including hepatic encephalopathy. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Additional cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]). BP at each clinical visit (as well as daily home monitoring for first cycle, after dose increases, and every 2 to 3 weeks thereafter); ECG and QTc assessment in patients at moderate- or high-risk of QTc prolongation (assess QTc monthly during the first 3 months and every 3 to 6 months thereafter); baseline echocardiography in high- and very high-risk patients (repeat every 3 months during the first year and every 6 to 12 months thereafter); consider baseline echocardiography in low- and moderate-risk patients (consider repeating every 4 months during the first year for moderate-risk patients and every 6 to 12 months thereafter) (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F27378026"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lenvatinib is a multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. Inhibition of these receptor tyrosine kinases leads to decreased tumor growth and slowing of cancer progression. In hepatocellular carcinoma cell lines dependent on activated FGFR signaling (with a concurrent inhibition of FGF-receptor substrate 2α phosphorylation), lenvatinib exhibited antiproliferative activity. Combining lenvatinib with everolimus has demonstrated increased antiangiogenic and antitumor activity by decreasing human endothelial cell proliferation, tube formation, and VEGF signaling (in vitro) compared to either drug alone.</p></div>
<div class="block phk drugH1Div" id="F27378028"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Administration with a high fat meal (~900 calories; ~55% from fat, ~15% from protein, and ~30% from carbohydrates) decreased the rate of absorption and delayed the median T<sub>max</sub> from 2 hours to 4 hours, but did not affect the extent of absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 97 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 97% to 99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily enzymatic through CYP3A and aldehyde oxidase; nonenzymatic metabolism also occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~28 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~64%); urine (~25%).</p></div>
<div class="block phksp drugH1Div" id="F51198309"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: In a single 10 mg dose study of lenvatinib in patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment, or a single 5 mg dose in patients with severe (Child-Pugh class C) hepatic impairment, the dose-adjusted AUC of lenvatinib was 119%, 107%, and 180%, respectively, as compared to patients with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F29044382"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lenvima</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lenvima</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.1">
<a name="George.1"></a>George D. Systemic therapy of advanced clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33197225">
<a name="33197225"></a>Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(36):4317-4345. doi:10.1200/JCO.20.02672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/33197225/pubmed" id="33197225" target="_blank">33197225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29433850">
<a name="29433850"></a>Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet</i>. 2018. pii: S0140-6736(18)30207-30211. doi:10.1016/S0140-6736(18)30207-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/29433850/pubmed" id="29433850" target="_blank">29433850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lenvima.1">
<a name="Lenvima.1"></a>Lenvima (lenvatinib) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lenvima.2">
<a name="Lenvima.2"></a>Lenvima (lenvatinib) [product monograph]. Mississauga, Ontario, Canada: Eisai Limited; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35045221">
<a name="35045221"></a>Makker V, Colombo N, Casado Herráez A, et al; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer. <i>N Engl J Med</i>. Published online January 19, 2022. doi:10.1056/NEJMoa2108330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/35045221/pubmed" id="35045221" target="_blank">35045221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33616314">
<a name="33616314"></a>Motzer R, Alekseev B, Rha SY, et al; CLEAR Trial Investigators. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. <i>N Engl J Med</i>. 2021;384(14):1289-1300. doi:10.1056/NEJMoa2035716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/33616314/pubmed" id="33616314" target="_blank">33616314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26482279">
<a name="26482279"></a>Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncol</i>. 2015;16(15):1473-1482. doi:10.1016/S1470-2045(15)00290-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/26482279/pubmed" id="26482279" target="_blank">26482279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234529">
<a name="25234529"></a>Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi:10.1016/j.joms.2014.04.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/25234529/pubmed" id="25234529" target="_blank">25234529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25671254">
<a name="25671254"></a>Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. <i>N Engl J Med</i>. 2015;372(7):621-630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/25671254/pubmed" id="25671254" target="_blank">25671254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 99962 Version 204.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
